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 Objective:  
   Proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2RA) rank in the top 5%  
of Kentucky Medicaid drug expenditures. These two classes of drugs are used to treat duodenal ulcer, 
gastric ulcer, gastroesophageal reflux disease (GERD), active benign ulcer, and erosive esophagitis. They 
can also be used to treat heartburn, acid indigestion, and sour stomach. The FDA approved labeling for 
these medications recommend use for no longer than 8 weeks; however, a review of the literature shows 
that many patients take these classes of medications for much longer periods of time. There are also 
increasing concerns about the adverse effects (e.g., hip fractures) associated with these medications, 
especially the PPIs.  An article featured in the Wall Street Journal (WSJ) on May 11th 2010 reported that 
more than 119 million prescriptions were written for PPIs in the U.S. in 2009 and some doctors believe 
these medications are over-prescribed for less severe ailments like indigestion or upset stomach.  
 
   The fact is that nearly everyone has seen commercials about heartburn and most people have 
experience with this condition. These agents are being consumed in large amounts and those who use 
them are probably unaware of the potential risk they are taking. Consumers have been led to believe for 
nearly two decades that these are ‘benign’ drugs although several studies have shown these medications 
are linked to infections, drug interactions, fracture and unnecessary drug expenditure. The Kentucky 
Medicaid spending is rising at twice the rate of the budget, hence a protocol (for example regarding 
length of therapy, or which patients are appropriate candidates for therapy) may help reduce 
expenditures for these medications and thus reduce the budget gap. The objective of this study is to 
determine the incidence of hip fracture associated with proton pump inhibitor (PPI) and/or H2 receptor 
antagonist use in the Kentucky Medicaid population and to determine the total expenditures associated 
with treating these hip fractures.  
 
Background: 
 
 The advent of medications such as proton pump inhibitors (PPI) and H2 receptor antagonists 
(H2RA) have changed and revolutionized the management of acid-related diseases such as 
gastroesophageal reflux disease (GERD).There has been a great deal of interest in acid-suppressing 
medications because they are among the most commonly prescribed medications1 in the United States. 
In fact global pharmaceutical sales for acid-suppressing therapies exceeded $24 billion dollars in 2006.1  
 These agents carry an FDA labeled indication for short-term (4-8 weeks) therapy of duodenal 
ulcer, gastric ulcer, gastroesophageal reflux disease (GERD), active benign ulcer, and erosive esophagitis. 
In treatment of heartburn, acid indigestion, and sour stomach, the labeled indication is for 14 days of 
therapy, then repeat treatment after 4 months if needed2. Since most patients take these medications 
for periods greater than their indication21, there have been several reports about adverse effects 
associated with chronic use, one of them being hip fractures. Hip fractures are a major cause of 
morbidity and mortality; more than 329,000 persons are hospitalized annually with hip fractures in the 
United States and the mortality rate is 5-10% after one month and about 30% after one year3.  The 
incidence and the economic consequences of hip fracture are substantial. Hence, the Kentucky Medicaid 
program may be able to institute some policies to control the use of these agents.  
   The table below shows the total drug expenditure of Kentucky Medicaid for PPIs and H2RAs and 
the cost associated with medical procedures for hip surgery from 2004 to 2009 (included in the drug 
costs are individuals’ out-of-pocket payments and Medicaid costs; included in the hip surgery costs are 
individuals’ out-of-pocket costs, Passport costs, Medicare and Medicaid costs) 4. In other words, Kentucky 
Medicaid spends considerable tax dollars on the use of PPIs and H2RAs, hence if there is a causal effect 
between these medications and hip fracture, Medicaid should be encouraged to adopt a policy to ensure 
they are used appropriately thereby limiting Medicaid recipients’ risk for these potentially costly adverse 
effects. 
 
Table 1: Drug expenditure of Kentucky Medicaid for PPIs and H2RAs and medical procedures costs for hip 
fracture (2004-2009) 
 
Year Total Spent (PPIs) [$] Total Spent (H2RAs) [$] Hip Fracture cost [$] 
2004 23,219,922 10,964,607 1,004,198 
2005 22,405,920 6,638,345 956,855 
2006 12,601,746 3,449,352 981,494 
2007 13,804,347 3,059,668 1,015,387 
2008 18,253,050 2,600,807 936,601 
2009 28,620,537 2,027,572 886,589 
 
H2 receptor antagonists (H2RA) and PPIs effectively raise gastric pH. PPIs suppress acid secretion 
by gastric parietal cells which results in the inhibition of acid secretion from all physiologic stimuli.5 H2 
receptor antagonists inhibit histamine stimulated acid secretion. H2 receptors may be upregulated by H2 
receptor antagonist, which can result in tolerance over time.6 Tolerance has not been shown with PPIs.5 
Several recent studies in human volunteers have suggested that short-term use of acid suppressing 
medications can decrease calcium absorption 7-9, which may lead to calcium deficiency. Since calcium 
absorption is reduced in individuals taking acid suppression medications, the question arises about the 
long-term “maintenance” use of these therapies and the risk of bone fractures or osteoporosis.  
Decreased calcium absorption has been linked to increased risk of fracture, especially among older 
women with low calcium intake10, 11. 
Some H2 receptor antagonists (H2RA) and PPIs can be found over-the-counter (OTC) and hence 
are easily accessible. As more patients self-medicate without consulting their physician and pharmacist, 
it further worsens the problems associated with the adverse effects and costs associated with these 
drugs. 
In May 2010, the U.S Food and Drug Administration issued a warning about the use of PPIs and 
increased risk of bone fractures. The greatest risk for these fractures (hip, wrist and spine) were in 
patients who received high doses or used them for greater than 1 year. The majority of the patients in 
the epidemiologic studies were greater than 50 years of age with the risk of fractures being limited to 
this age group.  To date, no randomized clinical trials of acid suppressing therapies have found an 
increased risk of hip, wrist or spine fractures. 
Literature review:  
A summary of the epidemiological studies that have evaluated fracture risk with PPIs and H2RAs 
use is presented in Table 2 below.  
 A retrospective case control study by Corley et al. 12 revealed that patients with hip fractures 
were more likely than controls to have previously received a greater  than 2-year supply of PPIs or H2RA, 
odds ratio (OR) = 1.30 (95% CI, 1.21-1.39). Corley and colleagues concluded that use of drugs that inhibit 
gastric acid is associated with an increased risk of hip fracture; however, the association was only found 
among persons with at least one other risk factor for hip fracture. This study did not consider alcohol 
use, diet, physical activity, body mass index, smoking histories of the patients hence there is a possibility 
of bias. In addition, some members who took over-the-counter PPIs and H2RAs may be classified as 
“unexposed” hence decreasing the strength of the association.  
Another study by Yang et al. 13 concluded that there is an increased risk of hip fracture for PPI 
use greater than 1 year; adjusted odds ratio (aOR)  = 1.44 (95% CI, 1.30–1.59). The risk of hip fracture 
increased with a high dose (>1.75 doses/day); aOR = 2.65 (95% CI, 1.80-3.90). The risk of hip fracture 
also increased with longer duration of PPI use: 1 year, aOR = 1.22 (95% CI, 1.15-1.30) and 4 year, aOR = 
1.59 (95% CI, 1.39-1.80). Some of the limitations in this study were incomplete information about the 
BMI of 33% of the patients, inability to determine prior PPI use of patients enrolled in the database; 
hence there could have been an underestimation of the duration of exposure. There was no information 
on OTC calcium supplement use.  
Vestergaard et al. 14 reported that use of PPIs was associated with an increased risk of fracture 
within the last year (OR =1.18, 95% CI, 1.12-1.43) but no dose-response or duration-response 
relationships were present. H2RAs were associated with a decreased fracture risk if they had been used 
within the last year (OR = 0.88, 95% CI 0.82-0.95). During the study period, PPIs were available only on 
prescription and H2RAs were available as OTC. Hence this introduces a bias because the database does 
not contain information on drugs sold OTC. This may have underestimated the risk associated with these 
drugs.  
Targownik et al. 15 used a Canadian administrative claim database to determine if the use of PPIs 
has any association with an increased risk of hip fracture. They also explored if there is a relationship 
between duration of exposure to PPIs and osteoporosis-related fractures. They concluded that an 
exposure of 7 or more years was associated with increased risk of an osteoporosis-related fracture 
(adjusted OR 1.92, 95% CI, 1.16-3.16, p= 0.011). There was also an increased risk of hip fracture after 5 
or more years of exposure (adjusted OR 1.62, 95% CI1.02-2.58, p= 0.04). The study has some limitations 
such as lack of information about OTC calcium supplements, vitamin D supplements, tobacco and 
alcohol use.  
Kaye et al. 16 estimated the relative risk of hip fracture associated with proton pump inhibitor 
(PPI) use in a population without major risk factors. This study was a 2-phase study. In phase 1, 4414 
case patients (aged 50-79 yrs) with an incident hip fracture and at least 2 years of recorded history in 
the database were analyzed. Phase 2 (a sub population of phase 1) included 1098 case patients 
identified as having no major medical risks for hip fracture. The results indicated that the relative risk 
(RR) for hip fracture among patients who received any PPI prescription was 0.9 (95% CI, 0.7–1.11) 
compared with those with no PPI prescription.  In other words, they found no evidence of an increased 
risk of hip fracture with PPI use. One caveat for their research was that patients at risk for fracture were 
excluded from the analysis.  
Yu et al. 17 used dual-energy X-ray absorptiometry and assessed baseline use of proton pump 
inhibitors (PPIs) and/or H2 receptor antagonists (H2RAs) in 5,755 men and 5,339 women. Medication 
use and bone mineral density (BMD) were assessed, and hip and other nonspine fractures were 
documented. On multivariate analysis, men using either PPIs or H2RAs had lower cross-sectional bone 
mass. No significant BMD differences were observed among women. However, there was an increased 
risk of nonspine fracture among women using PPIs (relative hazard [RH] = 1.34, 95% confidence interval 
[CI] 1.10-1.64). PPI use was also associated with an increased risk of nonspine fracture in men but only 
among those who were not taking calcium supplements (RH = 1.49, 95% CI 1.04-2.14). H2RA use was not 
associated with nonspine fractures, and neither H2RA use nor PPI use was associated with incident hip 
fractures in men or women. The use of PPIs in older women, and perhaps older men with low calcium 
intake, may be associated with a modestly increased risk of nonspine fracture. 
Some of these studies have identified a possible correlation between acid suppressing therapies 
and bone fracture. A major shortcoming is the possibility of residual confounders unidentified by the 
administrative databases used to analyze this relationship. Some confounders are inability to track OTC 
use of these medications, and the fact that some of these databases do not report tobacco and alcohol 
use in the patients. These introduce a bias and decrease the validity and reliability of these studies. 
Another issue is that these studies are retrospective in nature and there are no randomized clinical 
studies that have been done to establish the relationship between the incidence of fracture and acid 
suppressive therapy use.  
Methodology: 
This is a retrospective case-control study of pharmacy and medical claims from the Kentucky 
Medicaid database of patients on acid suppressing therapy with an incident diagnosis of hip fracture 
(ICD-9-CM) codes 820.0 to 821.20 (hip or femur fractures) between January 1, 2000 and December 31, 
2009. The index date is the fracture date. Enrollment in Medicaid has to be continuous at least 18 
months prior to the index date. For each case, matched controls were randomly selected from the 
Kentucky Medicaid Database. Controls were chosen from among eligible adult members who lacked a 
diagnosis of a hip fracture at the index date of the matched case. The controls also had 18 months of 
continuous membership before the index date. Pharmacy data were identified using the National Drug 
Code (NDC). Included in the pharmacy data were the drug dispensed, date the drug was dispensed, the 
frequency of refills, directions for use and amount paid. Medical claims were identified by using the 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Included 
in the medical claims data were date of service, and amount paid. In addition, data were available for 
age, gender, and plan enrollment time for each patient.  
 For comparisons of proportions, chi-square statistics were used. A conditional logistic regression 
model was used to estimate the relative magnitude in relation to the use of PPIs and H2RAs. The 
primary exposure for the analysis is acid suppressing therapy of more than one year before the index 
date. The one year duration was used because alterations in fracture risk due to the use of other 
medications, such as bisphosphonates, thiazide diuretics, and corticosteroids were apparent after 1 year 
of exposure.18, 19 Medication adherences for potential confounders will be measured by medication 
possession ratio (MPR). MPR of at least 80% is required for inclusion. Through retrospective drug claims 
analysis, MPR looks at medication refill history over a period of time and calculates how many doses of 
medication a patient obtained during the study period compared to how many doses should have been 
obtained.20   
The primary outcome of the study is to determine if there is an association between acid 
inhibition and hip fractures. I also evaluated whether fracture risk is generally associated with other 
commonly used medications, which may suggest confounding.  The study will utilize standard analytic 
techniques for evaluating case-control studies and conditional logistic regression. All definitions and 
modeling strategies were planned a priori. All statistical analyses were performed at a significance level 
of 0.05 in SAS statistical package version 9.2 SAS Institute Inc., Cary, North Carolina). 
 
 
MPR20=  Sum of days supply of drugs                  
  [# of days between first and last                    
  fill plus days’ supply of last fill] 
Table 2: Epidemiological Studies Evaluating Fracture Risk with Proton Pump Inhibitors (PPIs) 
Study Study time period Study population Finding related to PPIs 
 Vestergaard 
2006 
1/1/2000 – 
12/31/2000 
 124,655 cases with 
fractures 
 373,962 matched 
controls 
 All ages Data 
source: Denmark 
health database 
 
PPI use within the last year 
 Overall fracture risk, Odds Ratio (OR) = 1.18 (95% CI, 1.12–1.43)  
 Risk of hip fracture, OR = 1.45 (95% CI, 1.28–1.65)  
 Risk of spine fracture, OR = 1.60 (95% CI, 1.25–2.04)  
 Risk of forearm fracture, OR = 0.95 (0.82-1.11)  
 No dose-response relationship seen with PPIs and fracture risk: 
(DDD [defined daily doses] were the number of doses in a year) 
 Yang 2006 1987 - 2003  13,556 cases with 
fractures 
 135,386 matched 
controls 
 Ages ≥ 50 years  
 Data source: 
U.K./GPRD 
 
 Risk of hip fracture, PPI use > 1 year 
adjusted Odds Ratio (aOR)± = 1.44 (95% CI, 1.30–1.59)  
 Risk of hip fracture increased with high-dose PPI use > 1 year: 
(dose defined as dose/day, >1.75 doses/day) 
aOR = 2.65 (95% CI, 1.80-3.90)  
 Risk of hip fracture increased with longer duration of PPI use   
o 1 yr, aOR = 1.22 (95% CI, 1.15-1.30)  
o 4 yr, aOR = 1.59 (95% CI, 1.39-1.80) 
 
 Targownik 2008 
 
 
 
 
1996 – 2004 
 
 
 
 15,792 cases with 
fractures 
 47,289 matched 
controls 
 Ages ≥ 50 years  
 Data source: 
PHRDR/ Manitoba, 
Canada 
 Risk of hip, wrist, spine fractures with PPI use ≥ 7 years 
adjusted Odds Ratio (aOR) ¥ = 1.92 (95% CI, 1.16–3.18)  
 Risk of hip fracture increased with longer duration of use   
o PPI use ≥ 5 years, aOR = 1.62 (95% CI, 1.02–2.58)  
o PPI use ≥ 6 years, aOR = 2.49 (95% CI, 1.33-4.67)  
o PPI use ≥ 7 years, aOR = 4.55 (95% CI, 1.68–12.29) 
 Kaye 2008 
 
1995 - 2005  1,098 cases with 
fractures 
 10,923 matched 
controls  
 Ages 50 – 70 
years  
 Data source: 
U.K/GPRD 
 
 Estimated Relative Risk (RR) of hip fracture = 0.9 (95% CI, 0.7–1.11) 
(Patients at risk for fracture were excluded from the analysis)  
 Risk of hip fracture not detected with increased number of PPI 
prescriptions 
 
 Corley 2010 
 
1995-2007  33,752 cases with 
fractures  
 130,471 matched 
controls  
 Ages ≥ 18 years  
 Data source: 
KPNC/ California, 
USA 
 
 Risk of fracture with ≥ 2 years of PPI use and 1 other risk factor 
Odds Ratio (OR) = 1.30 (95% CI, 1.21–1.39)   
o Risk factors: alcohol abuse, arthritis, diabetes, kidney disease, 
glucocorticoids, cerebrovascular disease, dementia, epilepsy, 
gait disorder, hemiplegia, psychoses, smoking, visual 
impairment, anxiolytic use  
 Risk of fracture increased with higher PPI dose: 
(dose = number of pills per day >1.5) 
OR = 1.41 (95% CI, 1.21-1.64)  
 Risk of fracture did not consistently increase with longer duration of use 
 
 Yu 2008 
 
 
 
 
Women: 7.6 years 
mean follow-up   
Men: 5.6 years 
mean follow-up   
 
 Women (4,574 
non-PPI users and 
234 PPI users)  
 Men (4,920 non-
PPI users and 487 
PPI users) Ages ≥ 
65 years 
 Data source: 
 Risk of hip fracture   
o Women: adjusted Relative Hazard (aRH)= 1.16 (95% CI, 0.80-
1.67)  
o Men: aRH = 0.62 (95% CI, 0.26-1.44)  
 Risk of nonspine fracture   
o Women: aRH = 1.34 (95% CI, 1.10-1.64)  
o Men: aRH = 1.21 (95% CI, 0.91-1.62) 
 MrOS/SOF 
 Gray 2010 7.8 years, mean 
follow-up 
 2,831 PPIs users  
 127,756 non-PPIs 
users  
 Post-menopausal 
women ages 50 – 
79 years  
 Data source: WHI 
OS/WHI CT 
 
 Risk of total fractures 
adjusted Hazard Ratio (aHR) ≠ = 1.25 (95% CI, 1.15-1.36)  
 Risk of hip fracture, aHR = 1.00 (95% CI, 0.71-1.40)  
 Risk of spine fracture, aHR = 1.47 (95% CI, 1.18-1.82)  
 Risk of wrist fracture, aHR = 1.26 (95% CI, 1.05-1.51)  
 No consistent trend for fracture risk with duration of use 
 
Results: 
Table 3 shows baseline characteristics of the hip fracture cases and controls. There were 
500,910 patients without hip fracture and 2,634 patients with hip fracture; hence the baseline 
characteristics for the two populations were significantly different. The fracture cases more often 
were females. Fracture cases were prominent in individuals greater than 50 years and also residents 
of rural area. The comorbidity and use of drugs in general were higher among cases than controls.  
Hip fracture cases were also significantly more likely to have a medical diagnosis that had known 
associations with either hip fracture or the risk of falling which is consistent with findings from 
previous studies.13, 15 
Table 3: Characteristics of hip fracture cases and controls 
 
Variable Cases (n = 2,634) Controls (n = 500,910) Adjusted OR (95% CI) 
Gender    
Male 685 (26.01) 187,836 (37.50) 0.63 (0.58–0.69) 
Female 1,949 (73.99) 313,074 (62.50) Reference 
Region    
Urban  1,010 (38.34) 196,196 (39.17) 1.06 (0.98–1.16) 
Rural 1,624 (61.66) 304,714 (60.34) Reference 
Age    
≥50 2,157 (81.89) 199,913 (39.91) 3.92 (3.51–4.37) 
<50 477 (18.11) 300,997 (60.09) Reference 
Race    
Black 178 (6.76) 55,177 (11.02) 0.72 (0.61-0.84) 
White 2,308 (87.62) 416,844 (83.22) Reference 
Other 148 (5.62) 28,889 (5.77) 0.75 (0.63–0.89) 
Medication use    
Thiazide  363 (13.78) 48,842 (9.75) 0.79 (0.70–0.89) 
Corticosteroid 51 (1.94) 5,192 (1.04) 0.79 (0.59–1.05) 
Estrogen 26 (0.99) 6,482 (1.99) 0.53 (0.36–0.78) 
Antiparkinsonian 93 (3.53) 8,755 (1.75) 1.11 (0.90–1.37) 
Antidepressants 817 (31.02) 150,314 (30.01) 0.64 (0.58–0.70) 
NSAIDS 547 (20.77) 163,194 (32.58) 0.71 (0.64–0.79) 
Statin 54 (2.05) 10,830 (2.16) 0.83 (0.72–0.97) 
Thyroid 243 (9.23) 26,236 (5.24) 0.47 (0.36–0.62) 
Bisphosphonates 55 (2.09) 2,161 (0.43) 1.84 (1.40–2.43) 
Anticoagulants 207 (7.86) 13.632 (2.72) 1.17 (1.00–1.36) 
Calcitonin 90 (3.42) 5,107 (1.02) 1.12 (0.90–1.39) 
Sedatives 779 (29.57) 88,367 (17.64) 1.36 (1.24–1.49) 
Health Condition    
Arthritis 15 (0.57) 1,256 (0.25) 1.38 (0.82–2.31) 
Cerebrovascular disease 453 (17.20) 22,890 (4.57) 1.36 (1.21–1.52) 
Hemiplegia 15 (0.57) 1,214 (0.24) 0.81 (0.48–1.36) 
Asthma 159 (6.04) 28,197 (5.63) 0.78 (0.66–0.93) 
Dementia psychoses 595 (22.59) 66,652 (13.31) 1.53 (1.39–1.69) 
Diabetes Mellitus 673 (25.55) 56,174 (11.21) 1.05 (0.95–1.16) 
Thyroid disease 156 (5.92) 18,938 (3.78) 1.15 (0.96–1.38) 
Ischemic Heart Disease  450 (17.07) 36,585 (7.30) 1.04 (0.93–1.16) 
Epilepsy 85 (3.23) 8.017 (1.60) 1.94 (1.55–2.43) 
Gait disorder 123 (4.67) 4,871 (0.97) 2.23 (1.84–2.70) 
Peptic ulcer disease 38 (1.44) 3.812 (0.76) 0.88 (0.63–1.21) 
GERD 176 (6.68) 24,176 (4.83) 0.83 (0.71–0.97) 
Visual Impairment 743 (28.21) 120,756 (24.11) 1.07 (0.98–1.17) 
Chronic kidney disease 135 (5.13) 6,196 (1.24) 1.73 (1.45–2.08) 
Charlson Index     
0 1,014 (38.50) 361,866 (72.24) Reference 
1 1,620 (61.50) 139,044 (27.76) 2.07 (1.87–2.29) 
 
The relationship between use of PPIs, H2RAs and hip fractures is shown in Table 4. An MPR greater than 
80% for PPIs and H2RAs use was statistically significantly associated with an increased OR for hip 
fracture. The multivariable adjusted OR for all potential confounders for hip fracture associated with PPI 
and H2RA therapies with more than one year use was 2.08 (95% CI, 1.85-2.34; P<.0001) and 3.08 (95% 
CI, 2.77-3.44; P<.0001) respectively.  
 
Table 4. Association between PPIs and H2RAs Use and Hip Fracture Risk in a Population-Based Case-
Control Study 
 Variable Cases (n = 2,634) Controls (n = 500,910) Adjusted OR (95% CI) 
PPI ≥ 80% MPR 420 (15.95) 29,514 (5.89) 2.08 (1.85–2.34) 
PPI < 80% MPR 2,214 (84.05) 471,396 (94.11) Reference 
H2RA ≥ 80% MPR 485 (18.41) 24,194 (4.83) 3.08 (2.77–3.44) 
H2RA < 80% MPR 2,149 (81.59) 476,716 (95.17) Reference 
 
 
 
 
Discussion:  
 
In this population-based case-control study, I found a significant relationship between use of 
PPIs and H2RAs and the risk of hip fracture after controlling for potential confounders. This finding is 
consistent with previous studies. 12, 13, 14, 15 The risk of hip fracture was higher among subjects taking 
H2RAs compared with PPI. This is counterintuitive because PPIs are more potent acid suppressing 
therapy in comparison to H2RAs. Overall, the increased risk was confined to persons with certain other 
risk factors for hip fracture.  
There are several mechanisms by which acid suppressing therapies may increase hip fracture 
risks. The increased risk may be as a result of a decrease in calcium absorption. An acidic environment in 
the gastrointestinal tract facilitates the release of ionized calcium from insoluble calcium salts22. 
 One of the strengths of this study was the use of a computerized database allowing for a large-
scale population-based design and the use of data on exposure and confounders that are collected 
before the date of fracture. Thus recall bias did not influence data collection.  
 There are several potential limitations of this study; a number of possible confounding variables, 
including body mass index, physical activity, smoking, alcohol use, sun exposure and over-the-counter 
use of calcium/vitamin D supplements, which are associated with fracture were not available in the 
database. In addition some of the PPIs and H2RAs are over-the-counter (OTC) medications; hence some 
patients who took these OTC medications may have been classified as controls, which would have 
expected to decrease the strength of the association.  
 In summary, results of this study suggest that there is a significant relationship between PPIs 
and H2RAs use and hip fracture risk. Prospective randomized trial clinical studies are necessary to 
confirm my findings and an experimental study on the mechanism by which PPIs and H2RAs may 
increase hip fracture risk is necessary.  
 
Recommendations: 
 
A policy on appropriate acid-suppressing therapy use might be mandated by the Kentucky 
Medicaid program. This policy will essentially reduce cost by eliminating millions of dollars spent on 
unnecessary drug expenditure, thus closing the budget gap in Kentucky Medicaid program.  The policy 
should be in accordance with the FDA approved labeling of this class of drug. Some policies that may 
improve appropriate use of these agents are: 
 1. Prior authorization protocol for patients taking this medication for more than 8 weeks. A 
requirement for endoscopic diagnosis should be mandated beyond 8 weeks. 
2. Moving this drug class behind the counter just like pseudoephedrine containing products but 
not electronically monitoring these products. This will create an opportunity for patients to have 
a conversation with the pharmacist about appropriate drug use and most especially non-drug 
measures they can implement in avoiding heartburn and acid reflux. 
3. When prescribing these agents, consider whether a lower dose or shorter duration of 
therapy would adequately treat the patient's condition. 
4. Individuals at risk for osteoporosis should have their bone status managed according to current 
clinical practice, and should take adequate vitamin D and calcium supplementation. 
  
Lifestyle changes should be advocated in order to reduce symptoms of GERD. These changes could be: 
 
1. Avoid heart-burn triggering food such as orange juice, chocolate, tomato sauce, spicy foods, 
mint, garlic, and vinegar. These may vary from person to person. 
2. Staying upright for a few hours after eating and abstaining from exercise after right after eating 
3. Eating smaller meals, reducing caffeine and alcohol intake and avoiding cigarettes. 
4. Weight loss and incorporating physical activity. 
5. Wear looser-fitted clothes.  
6. Bending with your knees instead bending over at the waist. 
7. Elevate head of the bed.  
 
 
 
 
 
 
 
 
 
 
 
Appendix 
Passport is a health care plan that uses federal and state funds, through a Medicaid waiver, to pay for 
in-home alternatives to nursing home care for low-income, Medicaid eligible seniors. 
CPT codes used to determine the cost of hip fracture surgeries are: 27193, 27194, 27200, 27202, 27215, 
27216, 27217, 27218, 27220, 27222, 27226, 27227, 27228, 27230, 27232, 27235, 27236, 27238, 27240, 
27244, 27245, 27246, 27248, 27250, 27252, 27253, 27254, 27256, 27257, 27258, 27259, 27265, 27266, 
27267, 27268, and 27269.  
NDC is a unique 10 digit, 3-segment numeric identifier assigned to each medication intended for human 
use in the United States. 
ICD-9-CM is used to code and classify morbidity data from the inpatient and outpatient records, 
physician offices, and most National Center for Health Statistics (NCHS) surveys. 
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